Clinical Trial Update: A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease [Phase 3]

View source ↗

Summary

Phase 3 trial of GA-GCB enzyme replacement therapy for Gaucher disease type 1 has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease Type

Drugs mentioned

• Gene-Activated® Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy (glucocerebrosidase)

Snippet

Sponsor: Shire | Conditions: Gaucher Disease, Type 1 | Phase 3 | Status: COMPLETED | Results posted: 2010-09-10